{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:58:57Z","timestamp":1782377937459,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31910-5","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:06:34Z","timestamp":1765512394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and biological evaluation of mesalamine\u2013NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Misagh","family":"Yahya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Safaei-Ghomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolrasoul","family":"Haghir-Ebrahimabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Mojtabazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"10","key":"31910_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","volume":"330","author":"B Gros","year":"2023","unstructured":"Gros, B. & Kaplan, G. G. Ulcerative colitis in adults: A review. JAMA 330(10), 951\u2013965. https:\/\/doi.org\/10.1001\/jama.2023.15389 (2023).","journal-title":"JAMA"},{"key":"31910_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan, G. G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720\u2013727. https:\/\/doi.org\/10.1038\/nrgastro.2015.150 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"31910_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","volume":"1","author":"S Ghosh","year":"2007","unstructured":"Ghosh, S. & Mitchell, R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn\u2019s and Ulcerative Colitis Associations (EFCCA) patient survey. J. Crohns Colitis 1, 10\u201320. https:\/\/doi.org\/10.1016\/j.crohns.2007.06.005 (2007).","journal-title":"J. Crohns Colitis"},{"key":"31910_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","volume":"6","author":"A Dignass","year":"2012","unstructured":"Dignass, A. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J. Crohns Colitis 6, 991\u20131030. https:\/\/doi.org\/10.1016\/j.crohns.2012.09.002 (2012).","journal-title":"J. Crohns Colitis"},{"key":"31910_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.phrs.2015.07.005","volume":"100","author":"G Rogler","year":"2015","unstructured":"Rogler, G. Where are we heading to in pharmacological IBD therapy?. Pharmacol. Res. 100, 220\u2013227. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.005 (2015).","journal-title":"Pharmacol. Res."},{"key":"31910_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00449-024-03047-8","volume":"47","author":"M Govindarasu","year":"2024","unstructured":"Govindarasu, M., Vaiyapuri, M. & Kim, J. C. Protective effect of zinc oxide nanoparticles synthesized using Cassia alata for DSS-induced ulcerative colitis in mice model. Bioprocess Biosyst. Eng. 47, 1393\u20131407. https:\/\/doi.org\/10.1007\/s00449-024-03047-8 (2024).","journal-title":"Bioprocess Biosyst. Eng."},{"key":"31910_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","volume":"20","author":"C Le Berre","year":"2020","unstructured":"Le Berre, C., Roda, G., Nedeljkovic Protic, M., Danese, S. & Peyrin-Biroulet, L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin. Biol. Therapy 20, 363\u2013378. https:\/\/doi.org\/10.1080\/14712598.2019.1666101 (2020).","journal-title":"Expert Opin. Biol. Therapy"},{"key":"31910_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00205","author":"A Talevi","year":"2015","unstructured":"Talevi, A. Multi-target pharmacology: Possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2015.00205 (2015).","journal-title":"Front. Pharmacol."},{"key":"31910_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.2174\/1568026616666160927160620","volume":"17","author":"MD Oliveira Pedrosa","year":"2017","unstructured":"Oliveira Pedrosa, M. D. et al. Hybrid compounds as direct multitarget ligands: A review. Curr. Top. Med. Chem. 17, 1044\u20131079 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"31910_CR10","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.2174\/092986711797535344","volume":"18","author":"MN O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, M. N. & Meegan, J. M. Designed multiple ligands for cancer therapy. Curr. Med. Chem. 18, 4722\u20134737 (2011).","journal-title":"Curr. Med. Chem."},{"key":"31910_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","volume":"390","author":"A Lanas","year":"2017","unstructured":"Lanas, A. & Chan, F. K. Peptic ulcer disease. Lancet 390, 613\u2013624 (2017).","journal-title":"Lancet"},{"key":"31910_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1476-5381.2011.01509.x","volume":"165","author":"JL Wallace","year":"2012","unstructured":"Wallace, J. L. NSAID gastropathy and enteropathy: Distinct pathogenesis likely necessitates distinct prevention strategies. Br. J. Pharmacol. 165, 67\u201374 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"31910_CR13","first-page":"1251","volume":"4","author":"SH Hammoodi","year":"2022","unstructured":"Hammoodi, S. H., Ismael, S. S. & Mustafa, Y. F. Mutual prodrugs for colon targeting: A review. Eurasian Chem. Commun. 4, 1251\u20131265 (2022).","journal-title":"Eurasian Chem. Commun."},{"key":"31910_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cbdd.12292","volume":"84","author":"T Narsinghani","year":"2014","unstructured":"Narsinghani, T. & Sharma, R. Lead optimization on conventional non-steroidal anti-inflammatory drugs: An approach to reduce gastrointestinal toxicity. Chem. Biol. Drug Des. 84, 1\u201323 (2014).","journal-title":"Chem. Biol. Drug Des."},{"key":"31910_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2174\/1389557518666180330112416","volume":"18","author":"S Sehajpal","year":"2018","unstructured":"Sehajpal, S., Prasad, D. N. & Singh, R. K. Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs): A long march towards synthesis of safer NSAIDs. Mini. Rev. Med. Chem. 18, 1199\u20131219 (2018).","journal-title":"Mini. Rev. Med. Chem."},{"key":"31910_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo, H., Callaway, J. B. & Ting, J. P. Y. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677\u2013687. https:\/\/doi.org\/10.1038\/nm.3893 (2015).","journal-title":"Nat. Med."},{"key":"31910_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2019.00276","volume":"10","author":"Y Zhen","year":"2019","unstructured":"Zhen, Y. & Zhang, H. NLRP3 inflammasome and inflammatory bowel disease. Front. Immunol. 10, 276 (2019).","journal-title":"Front. Immunol."},{"key":"31910_CR18","first-page":"1","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S.-C. NF-\u03baB signaling in inflammation. Signal Transduct. Target. Ther. 2, 1\u20139 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"key":"31910_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821\u2013832 (2010).","journal-title":"Cell"},{"key":"31910_CR20","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1038\/s41598-018-26775-w","volume":"8","author":"AP Perera","year":"2018","unstructured":"Perera, A. P. et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci. Rep. 8, 8618 (2018).","journal-title":"Sci. Rep."},{"key":"31910_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-immunol-090122-045843","volume":"42","author":"O Foresto-Neto","year":"2024","unstructured":"Foresto-Neto, O., Menezes-Silva, L., Leite, J. A., Andrade-Silva, M. & C\u00e2mara, N. O. S. Immunology of kidney disease. Annu. Rev. Immunol. 42, 207\u2013233 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"31910_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43094-020-00057-7","volume":"6","author":"MF Bayan","year":"2020","unstructured":"Bayan, M. F. & Bayan, R. F. Recent advances in mesalamine colonic delivery systems. Future J. Pharm. Sci. 6, 43 (2020).","journal-title":"Future J. Pharm. Sci."},{"key":"31910_CR23","first-page":"393","volume":"58","author":"SE Berends","year":"2018","unstructured":"Berends, S. E. et al. Clinical pharmacokinetic and pharmacodynamic properties of 5-ASA compounds in the treatment of ulcerative colitis: A review. J. Clin. Pharmacol. 58, 393\u2013408 (2018).","journal-title":"J. Clin. Pharmacol."},{"key":"31910_CR24","doi-asserted-by":"publisher","first-page":"101319","DOI":"10.1016\/j.jscs.2021.101319","volume":"25","author":"M Govindarasu","year":"2021","unstructured":"Govindarasu, M. et al. In silico modeling and molecular docking insights of kaempferitrin for colon cancer-related molecular targets. J. Saudi Chem. Soc. 25, 101319 (2021).","journal-title":"J. Saudi Chem. Soc."},{"key":"31910_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588\u2013606 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31910_CR26","doi-asserted-by":"crossref","unstructured":"Chanput, W., Peters, V. & Wichers, H. THP\u20111 and\u202fU937\u202fCells. In The Impact of Food Bioactives on Health: In vitro and Ex Vivo Models, 147\u2013159 (2015).","DOI":"10.1007\/978-3-319-16104-4_14"},{"key":"31910_CR27","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.3390\/pr11082248","volume":"11","author":"\u0130 Gulcin","year":"2023","unstructured":"Gulcin, \u0130 & Alwasel, S. H. DPPH radical scavenging assay. Processes 11, 2248 (2023).","journal-title":"Processes"},{"key":"31910_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s13197-011-0251-1","volume":"48","author":"SB Kedare","year":"2011","unstructured":"Kedare, S. B. & Singh, R. P. Genesis and development of DPPH method of antioxidant assay. J. Food Sci. Technol. 48, 412\u2013422 (2011).","journal-title":"J. Food Sci. Technol."},{"key":"31910_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/molecules29051016","volume":"29","author":"P Theodosis-Nobelos","year":"2024","unstructured":"Theodosis-Nobelos, P., Marc, G. & Rekka, E. A. Design, synthesis and evaluation of antioxidant and NSAID derivatives with antioxidant, anti-inflammatory and plasma lipid-lowering effects. Molecules 29, 1016 (2024).","journal-title":"Molecules"},{"key":"31910_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.26554\/sti.2023.8.3.338-343","volume":"8","author":"EQ Jasim","year":"2023","unstructured":"Jasim, E. Q., Muhammad-Ali, M. A. & Almakki, A. S. Synthesis, characterization, and antibacterial activity of some mesalazine derivatives. Sci. Technol. Indones. 8, 338\u2013343. https:\/\/doi.org\/10.26554\/sti.2023.8.3.338-343 (2023).","journal-title":"Sci. Technol. Indones."},{"key":"31910_CR31","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1039\/C7NJ03332J","volume":"41","author":"V Gorantla","year":"2017","unstructured":"Gorantla, V. et al. Molecular hybrid design, synthesis and biological evaluation of N-phenyl sulfonamide-linked N-acyl hydrazone derivatives functioning as COX-2 inhibitors, new anti-inflammatory, antioxidant and antibacterial agents. New J. Chem. 41, 13516\u201313532. https:\/\/doi.org\/10.1039\/C7NJ03332J (2017).","journal-title":"New J. Chem."},{"key":"31910_CR32","doi-asserted-by":"publisher","first-page":"13161","DOI":"10.3390\/ijms222313161","volume":"22","author":"SJ Yoon","year":"2021","unstructured":"Yoon, S. J., Kang, G. Y., Yoon, Y. D. & Park, J. H. Anti-inflammatory effects of hirsutanol A in LPS-stimulated human monocytic U937 cells via suppression of NF-\u03baB and MAPK activation. Int. J. Mol. Sci. 22, 13161. https:\/\/doi.org\/10.3390\/ijms222313161 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"31910_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s42003-021-02479-2","volume":"4","author":"S Yoodee","year":"2021","unstructured":"Yoodee, S. et al. Effects of secretome derived from macrophages exposed to calcium oxalate crystals on renal fibroblast activation. Commun. Biol. 4, 959. https:\/\/doi.org\/10.1038\/s42003-021-02479-2 (2021).","journal-title":"Commun. Biol."},{"key":"31910_CR34","doi-asserted-by":"publisher","unstructured":"Cseke, L. J., Kaufman, P. B. & Podila, G. K. Real-time PCR-based gene expression analysis. In Handbook of Molecular and Cellular Methods in Biology and Medicine, 3rd ed., Chapter 6, 111\u2013122 (CRC Press, 2011). https:\/\/doi.org\/10.1016\/B978-0-12-385118-5.00006-2.","DOI":"10.1016\/B978-0-12-385118-5.00006-2"},{"key":"31910_CR35","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1111\/j.1572-0241.2000.03360.x","volume":"95","author":"H Bantel","year":"2000","unstructured":"Bantel, H. et al. Mesalazine inhibits activation of transcription factor NF-\u03baB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95, 3452\u20133457 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"31910_CR36","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3748\/wjg.v29.i6.1026","volume":"29","author":"FEM Ali","year":"2023","unstructured":"Ali, F. E. M. et al. Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study. World J. Gastroenterol. 29, 1026\u20131053. https:\/\/doi.org\/10.3748\/wjg.v29.i6.1026 (2023).","journal-title":"World J. Gastroenterol."},{"key":"31910_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.yexcr.2016.03.009","volume":"342","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells. Exp. Cell Res. 342, 184\u2013192. https:\/\/doi.org\/10.1016\/j.yexcr.2016.03.009 (2016).","journal-title":"Exp. Cell Res."},{"key":"31910_CR38","first-page":"12","volume":"34","author":"Z Zhong","year":"2016","unstructured":"Zhong, Z. et al. Autophagy, NLRP3 inflammasome and auto-inflammatory\/immune diseases. Clin. Exp. Rheumatol. 34, 12\u201316 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"31910_CR39","doi-asserted-by":"publisher","first-page":"124008","DOI":"10.1016\/j.carbpol.2025.124008","volume":"367","author":"H Mojtabazadeh","year":"2025","unstructured":"Mojtabazadeh, H. & Safaei-Ghomi, J. Sustainable electrochemical depolymerization of chitosan into glucosamine hydrochloride using N-hydroxyphthalimide as a redox catalyst. Carbohyd. Polym. 367, 124008. https:\/\/doi.org\/10.1016\/j.carbpol.2025.124008 (2025).","journal-title":"Carbohyd. Polym."},{"key":"31910_CR40","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.3390\/molecules28196918","volume":"28","author":"F Li","year":"2023","unstructured":"Li, F. et al. Glucosamine improves non-alcoholic fatty liver disease induced by high-fat and high-sugar diet through regulating intestinal barrier function, liver inflammation, and lipid metabolism. Molecules 28, 6918 (2023).","journal-title":"Molecules"},{"key":"31910_CR41","doi-asserted-by":"publisher","first-page":"1395008","DOI":"10.3389\/fchem.2024.1395008","volume":"12","author":"M Mousavi-Ebadi","year":"2024","unstructured":"Mousavi-Ebadi, M. & Safaei-Ghomi, J. Melamine phosphate-modified magnetic chitosan, a novel biocompatible catalyst for the synthesis of biological tetrahydrodipyrazolopyridine and pyrazolopyranopyrimidine derivatives. Front. Chem. 12, 1395008. https:\/\/doi.org\/10.3389\/fchem.2024.1395008 (2024).","journal-title":"Front. Chem."},{"key":"31910_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/biom12081163","volume":"12","author":"I Palenca","year":"2022","unstructured":"Palenca, I. et al. N-palmitoyl-D-glucosamine inhibits TLR-4\/NLRP3 and improves DNBS-induced colon inflammation through a PPAR-\u03b1-dependent mechanism. Biomolecules 12, 1163 (2022).","journal-title":"Biomolecules"},{"key":"31910_CR43","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1038\/s41598-019-42130-z","volume":"9","author":"H-W Chiu","year":"2019","unstructured":"Chiu, H.-W. et al. Glucosamine inhibits IL-1\u03b2 expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci. Rep. 9, 5603 (2019).","journal-title":"Sci. Rep."},{"key":"31910_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12950-020-00255-3","volume":"17","author":"F He","year":"2020","unstructured":"He, F. et al. N-acetylcysteine alleviates post-resuscitation myocardial dysfunction and improves survival outcomes via partly inhibiting NLRP3 inflammasome induced-pyroptosis. J. Inflamm. 17, 25 (2020).","journal-title":"J. Inflamm."},{"key":"31910_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/foods6100092","volume":"6","author":"SJ Hewlings","year":"2017","unstructured":"Hewlings, S. J. & Kalman, D. S. Curcumin: A review of its effects on human health. Foods 6, 92 (2017).","journal-title":"Foods"},{"key":"31910_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature25986","volume":"556","author":"EL Mills","year":"2018","unstructured":"Mills, E. L. et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556, 113\u2013117 (2018).","journal-title":"Nature"},{"key":"31910_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.intimp.2016.11.024","volume":"42","author":"W Wei","year":"2017","unstructured":"Wei, W. et al. Rhapontin ameliorates colonic epithelial dysfunction in experimental colitis through SIRT1 signaling. Int. Immunopharmacol. 42, 185\u2013194 (2017).","journal-title":"Int. Immunopharmacol."},{"key":"31910_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10787-024-01630-9","volume":"33","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Anti-inflammatory, anti-colitis, and antioxidant effects of columbianadin against DSS-induced ulcerative colitis in rats via alteration of HO-1\/Nrf2 and TLR4-NF-\u03baB signaling pathway. Inflammopharmacology 33, 341\u2013352 (2025).","journal-title":"Inflammopharmacology"},{"key":"31910_CR49","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1007\/s10787-024-01566-0","volume":"32","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. The role of quercetin in NLRP3-associated inflammation. Inflammopharmacology 32, 3585\u20133610 (2024).","journal-title":"Inflammopharmacology"},{"key":"31910_CR50","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.carpta.2025.100923","volume":"11","author":"M Mousavi-Ebadi","year":"2025","unstructured":"Mousavi-Ebadi, M., Safaei-Ghomi, J. & Mojtabazadeh, H. Anchoring cobalt nanoparticles on to the grafted mono(6-ethylene-diamino-6-deoxy)-\u03b2-cyclodextrin to magnetic chitosan for enhanced catalytic performance of the synthesis of pyrano[2,3-c]pyrazole-3-carboxylates. Carbohydr. Polym. Technol. Appl. 11, 100923. https:\/\/doi.org\/10.1016\/j.carpta.2025.100923 (2025).","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"31910_CR51","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s42003-023-05023-6","volume":"6","author":"S Mondal","year":"2023","unstructured":"Mondal, S. et al. Chitosan functionalized Mn(3)O(4) nanoparticles counteracts ulcerative colitis in mice through modulation of cellular redox state. Commun. Biol. 6, 647. https:\/\/doi.org\/10.1038\/s42003-023-05023-6 (2023).","journal-title":"Commun. Biol."},{"key":"31910_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.22075\/ppam.2024.33349.1091","volume":"4","author":"A Hashemi","year":"2024","unstructured":"Hashemi, A. et al. Structural and antibacterial properties of AgFe2O4 and Fe3O4 nanoparticles, and their nanocomposites. Progr. Phys. Appl. Mater. 4, 37\u201346. https:\/\/doi.org\/10.22075\/ppam.2024.33349.1091 (2024).","journal-title":"Progr. Phys. Appl. Mater."},{"key":"31910_CR53","doi-asserted-by":"publisher","first-page":"12773","DOI":"10.1039\/D5RA00587F","volume":"15","author":"H Mojtabazadeh","year":"2025","unstructured":"Mojtabazadeh, H. & Safaei-Ghomi, J. High conductivity graphite paste for radio frequency identification tag with wireless hydrogen sensor based on CeO2\u2013Fe2O3\u2013graphene oxide. RSC Adv. 15, 12773\u201312784. https:\/\/doi.org\/10.1039\/D5RA00587F (2025).","journal-title":"RSC Adv."},{"key":"31910_CR54","doi-asserted-by":"publisher","first-page":"98732","DOI":"10.3748\/wjg.v31.i5.98732","volume":"31","author":"L Mi","year":"2025","unstructured":"Mi, L. et al. Hollow cerium nanoparticles synthesized by one-step method for multienzyme activity to reduce colitis in mice. World J. Gastroenterol. 31, 98732. https:\/\/doi.org\/10.3748\/wjg.v31.i5.98732 (2025).","journal-title":"World J. Gastroenterol."},{"key":"31910_CR55","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/app11010438","volume":"11","author":"A Nedelcu","year":"2021","unstructured":"Nedelcu, A., Mosteanu, O., Pop, T., Mocan, T. & Mocan, L. Recent advances in nanoparticle-mediated treatment of inflammatory bowel diseases. Appl. Sci. 11, 438 (2021).","journal-title":"Appl. Sci."},{"key":"31910_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/JBR.0000000000000078","volume":"03","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects. J. Bio-X Res. 03, 157\u2013173. https:\/\/doi.org\/10.1097\/JBR.0000000000000078 (2020).","journal-title":"J. Bio-X Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31910-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:33:31Z","timestamp":1768480411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31910-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31910"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31910-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2060"}}